The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction

Journal of Virology

Volumn 73, Issue 8, 1999, Pages 6540-6550

  Swenson, Jennifer J ^a   Mauser, Amy E ^a   Kaufmann, William K ^b   Kenney, Shannon C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; ELECTROPHORETIC MOBILITY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; FIBROBLAST; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; TRANSACTIVATION; VIRUS EXPRESSION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0032775437     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.8.6540-6550.1999     Document Type: Article

References (70)

1. Campanero, M., and E. Flemington. 1997. Regulation of E2F through ubiquitin-proteasome-dependcnt degradation: stabilization by the pRb tumor suppressor protein. Proc. Natl. Acad. Sci. USA 94:2221-2226.
2. 1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J. 15:2748-2759.
3. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Dallie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5:3243-3249.
4. Cistulli, C., and W. Kaufmann. 1998. p53-dependent signaling sustains DNA replication and enhances clonogenic survival in 254 nm ultraviolet-irradiated human fibroblasts. Cancer Res. 58:1993-2002.
5. Cleaver, J. E. 1969. Repair replication of mammalian cell DNA: effects of compounds that inhibit DNA synthesis or dark repair. Radiat. Res. 37:334-348.
6. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr virus after gene transfer with a small cloned fragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085-4089.
7. Cox, M., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J. Virol. 64:313-321.
8. de Bruyn Kops, A., and D. Knipes. 1988. Formation of DNA replication structures in herpes virus-infected cells requires a viral DNA binding protein. Cell 55:868.
9. DeCaprio, J., J. Ludlow, J. Figge, J. Shew, C. Huang, W. Lee, E. Marsilio, E. Paucha, and D. Livingston. 1988. SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283.
10. Dignam, J., R. Lebovitz, and R. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489.
11. Dyson, N., P. M. Howley, K. Munger, and E. Harlow. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science 243:934-937.
12. el-Deiry, W., T. Tokino, V. Velculescu, D. Levy, R. Parsons, J. Trent, D. Lin, W. Mercer, K. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
13. Farrell, P. J., D. T. Rowe, C. M. Rooney, and T. Kouzarides. 1989. Epstein-Barr virus BZLF1 trans-activator specifically binds to consensus Ap1 site and is related to c-fos. EMBO J. 8:127-132.
14. Filatov, L., V. Golubovskaya, J. C. Hurt, L. Byrd, J. Phillips, and W. Kaufmann. 1998. Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts expressing human papillomavirus type 16 E6 protein. Oncogene 16:1825-1838.
15. Flemington, E. K., A. M. Borras, J. P. Lytle, and S. H. Speck. 1992. Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain. J. Virol. 66:922-929.
16. Flemington, E. K., J. P. Lytle, C. Cayrol, A. M. Borras, and S. H. Speck. 1994. DNA-binding-defective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities. Mol. Cell. Biol. 14:3041-3052.
17. Fortunato, E. A., M. H. Sommer, K. Yoder, and D. H. Spector. 1997. Identification of domains within the human cytomegalovirus major immediateearly 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other. J. Virol. 71:8176-8185.
18. Grand, R., J. Smiley, W. C. Russel, and R. Narin. 1997. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
19. Gruffat, H., N. Duran, M. Buisson, F. Wild, R. Buckland, and A. Sergeant. 1992. Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter. J. Virol. 66:46-52.
20. Gruffat, H., and A. Sergeant. 1994. Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R. Nucleic Acids Res. 22:1172-1178.
21. Gutsch, D., K. B. Marcu, and S. Kenney. 1994. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters. Cell. Mol. Biol. 40:747-760.
22. Hardwick, J. M., P. M. Liebennan, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
23. Hardwick, J. M., L. Tse, N. Applegren, J. Nicholas, and M. A. Veliuona. 1992. The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16. J. Virol. 66:5500-5508.
24. Hardy, S., M. Kitamura, T. Harns-Stansil, Y. Dai, and J. Pines. 1997 Construction of adenovirus vectors through cre-lox recombination. J. Virol. 71:1842-1849.
25. Harris, K., J. Christensen, E. Radany, and M. J. Imperiale. 1998. Novel mechanisms of E2F induction by BK virus large-T antigen: requirement of both the pRb-binding and the J domains. Mol. Cell. Biol. 18:1746-1756.
26. Henderson, S., D. Huen, M. Rowe, C. Dawson, G. Johnson, and A. B. Rickinson. 1993. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA 90:8479-8483.
27. Hiebert, S., M. Lipp, and J. Nevins. 1989. E1A-dependent transactivation of the human myc promoter is mediated by the E2F factor. Proc. Natl. Acad. Sci. USA 86:3594-3598.
28. Hilton, M., D. Mounghane, T. McLean, N. Contractor, J. O'Neil, K. Carpenter, and S. L. Bachenheimer. 1998, Induction by herpes simplex virus of free and heteromeric forms of E2F transcription factor. Virology 213:624-638.
29. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369.
30. Hofmann, F., F. Martelli, D. Livingston, and Z. Wang. 1996. The retinoblastoma gene product protects E2F1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10:2949-2959.
31. Holley-Guthrie, E. A., E. B. Quinlivan, E. C. Mar, and S. Kenney. 1990. The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753-3759.
32. Imperiale, M. J., and J. R. Nevins. 1984. Adenovirus 5 E2 transcription unit: an E1A-inducible promoter with an essential element that functions independently of position or orientation. Mol. Cell. Biol. 4:875-882.
33. Jault, F. M., J. M. Jault, F. Ruchti, E. A. Fortunato, C. Clark, J. Corbeil, D. D. Richman, and D. H. Spector. 1995. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J. Virol. 69:6697-6704.
34. Johnson, D. G., J. K. Schwarz, W. D. Cress, and J. R. Nevins. 1993. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349-352.
35. 1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J. Virol. 71:2905-2912.
36. Kaufmann, W., J. Schwartz, J. Hurt, L. Byrd, D. Galloway, E. Levedakou, and L. Pedneault. 1997. Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ. 8:1105-1114.
37. Kenney, S., E. Holley-Guthrie, E. C. Mar, and M. Smith. 1989. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 63:3878-3883.
38. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2395. In B. N. Fields, D. M. Knipe, P. M. Howley, M. Hirsch, R. Chanock, J. Melnick, T. Monath, B. Roizman, and J. E. Streib (ed.), Fields virology, 3rd ed. Lippincott-Raven, New York, N.Y.
39. Kowalik, T. F., J. DeGregori, J. K. Schwarz, and J. R. Nevins. 1995. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol. 69:2491-2500.
40. Lane, D., and L. Crawford. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263.
41. Lazebnik, Y., S. Kaufmann, S. Desnoyers, G. Poirier, and W. Earnshaw. 1994. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346-347.
42. Levine, A. 1990. p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 177:419-426.
43. Lieberman, P. M., J. M. Hardwick, and S. D. Hayward. 1989. Responsiveness of the Epstein-Barr virus Notl repeat promoter to the Z transactivator is mediated in a cell-type specific manner by two independent signal regions. J. Virol. 63:3040-3050.
44. Liu, C., N. D. Sista, and J. S. Pagano. 1996. Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J. Virol. 70:2545-2555.
45. Lu, M., and T. Shenk. 1996. Human Cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S. Virology 70:8850-8857.
46. Margolis, M., S. Pajovic, E. Wong, M. Wade, R. Jupp, J. Nelson, and J. Azizkhan. 1995. Interaction of the 72-kilodalton human Cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription. J. Virol. 69:7759-7767.
47. Muralidhar, S., J. Doniger, E. Mendelson, J. Araujo, F. Kashanchi, N. Azumi, J. Brady, and L. Rosenthal. 1996. Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. J. Virol. 70:8691-8700.
48. Pajovic, S., E. Wong, A. Black, and J. Azizkhan. 1997. Identification of a viral kinase that phospborylates specific E2Fs and pocket proteins. Mol. Cell. Biol. 17:6459-6464.
49. Poma, E., T. Kowalik, L. Zhu, J. H. Sinclair, and E. Huang. 1996. The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter. J. Virol. 70:7867-7877.
50. Quinlivan, E. B., E. A. Holley-Guthrie, M. Norris, D. Gutsch, S. L. Bachenheimer, and S. C. Kenney. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21:1999-2007.
51. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J. Virol. 72:7978-7984.
52. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p, 2397-2446. In B. N. Fields, D. M. Knipe, P. M. Howley, R. Chanock, J. Melnick, T. Monath, B. Roizman, and S. Straus (ed.), Fields virology. Lippincott-Raven, New York, N. Y.
53. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3116.
54. Sandstrom, P., and T. Buttke. 1993. Autocrine production of extracellular catalase prevents apoptosis of the human CEM T-cell line in serum-free medium. Proc. Natl. Acad. Sci. USA 90:4708-4712.
55. Sarnow, P., Y. Ho, J. Williams, and A. Levine. 1982. Adenovirus E1b-58 kd tumor antigen and SV40 large T antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387-394.
56. Shandan, F. F., L. M. Cowsert, and L. P. Billarreal. 1994. n-Butyrate, a cell cycle blocker, inhibits the replication of polyomaviruses and papillomaviruses but not that of adenoviruses and herpesviruses. J. Virol. 68:4785-4796.
57. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517.
58. Stubdal, H., J. Zalvide, K. Campbell, C. Schweitzer, T. Roberts, and J. DeCaprio. 1998. Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol. Cell. Biol. 17:4979-4990.
59. Stubdal, H., J. Zalvide, and J. DeCaprio. 1998. Simian virus 40 large T antigen alters the phosphorylation state of the Rb-related proteins p130 and p107. J. Virol. 70:2781-2788.
60. Swenson, J. J. 1998. Unpublished data.
61. Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EB DNA fragment. J. Virol. 57:1016-1022.
62. Takase, K., C. A. Kelleher, N. Terada, J. F. Jones, J. J. Lucas, and E. W. Gelfand. 1996. Dissociation of EBV genome replication and host cell proliferation in anti-IgG-stimulated Akata cells. Clin. Immunol. Immunopathol. 81:168-174.
63. Takimoto, T., M. Kamide, and R. Umeda. 1984. Establishment of Epstein-Barr virus (EBV) associated nuclear antigen (EBNA) positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch. Oto-Rhino-Laryngol. 239: 87-92.
64. Urier, G., M. Buisson, P. Chambard, and A. Sergeant. 1989. The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J. 8:1447-1453.
65. Weinberg, R. 1995. E2F and cell proliferation: a world turned upside down. Cell 85:457-459.
66. Werness, B., A. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
67. Whyte, P., N. Williamson, and E. Harlow. 1989. Cellular targets for transformation by the adenovirus E1A proteins. Cell 56:67-75.
68. Zacny, V., J. Wilson, and J. S. Pagano. 1998. The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle. J. Virol. 72:8043-8051.
69. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194-9199.
70. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1929-1938.